Clinical features of polymyalgia rheumatica and giant cell arteritis

被引:161
作者
Salvarani, Carlo [1 ]
Pipitone, Nicolo [1 ]
Versari, Annibale [2 ]
Hunder, Gene G. [3 ]
机构
[1] Azienda Osped ASMN, Ist Ricovero & Cura Carattere Sci, Rheumatol Unit, Dept Internal Med, I-42123 Reggio Emilia, Italy
[2] Azienda Osped ASMN, Ist Ricovero & Cura Carattere Sci, Nucl Med Unit, Dept Adv Technol, I-42123 Reggio Emilia, Italy
[3] Mayo Clin, Coll Med, Div Rheumatol, Dept Med, Rochester, MN 55901 USA
关键词
PLACEBO-CONTROLLED TRIAL; CRANIAL ISCHEMIC COMPLICATIONS; SYSTEMIC INFLAMMATORY RESPONSE; ERYTHROCYTE SEDIMENTATION-RATE; POSITRON-EMISSION-TOMOGRAPHY; LARGE-VESSEL VASCULITIS; POPULATION-BASED COHORT; C-REACTIVE PROTEIN; TEMPORAL ARTERY; DOUBLE-BLIND;
D O I
10.1038/nrrheum.2012.97
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are inflammatory diseases that typically affect white individuals >50 years. Women are affected similar to 2-3 times more often than men. PMR and GCA occur together more frequently than expected by chance. The main symptoms of PMR are pain and stiffness in the shoulders, and often in the neck and pelvic girdle. Imaging studies reveal inflammation of joints and bursae of the affected areas. GCA is a large-vessel and medium-vessel arteritis predominantly involving the branches of the aortic arch. The typical clinical manifestations of GCA are new headache, jaw claudication and visual loss. PMR and GCA usually remit within 6 months to 2 years from disease onset. Some patients, however, have a relapsing course and might require long-standing treatment. Diagnosis of PMR and GCA is based on clinical features and elevated levels of inflammatory markers. Temporal artery biopsy remains the gold standard to support the diagnosis of GCA; imaging studies are useful to delineate large-vessel involvement in GCA. Glucocorticoids remain the cornerstone of treatment of both PMR and GCA, but patients with GCA require higher doses. Synthetic immunosuppressive drugs also have a role in disease management, whereas the role of biologic agents is currently unclear.
引用
收藏
页码:509 / 521
页数:13
相关论文
共 159 条
[31]   Th17 and Th1 T-Cell Responses in Giant Cell Arteritis [J].
Deng, Jiusheng ;
Younge, Brian R. ;
Olshen, Richard A. ;
Goronzy, Joerg J. ;
Weyand, Cornelia M. .
CIRCULATION, 2010, 121 (07) :906-U107
[32]   AZATHIOPRINE IN GIANT-CELL ARTERITIS POLYMYALGIA RHEUMATICA - A DOUBLE-BLIND-STUDY [J].
DESILVA, M ;
HAZLEMAN, BL .
ANNALS OF THE RHEUMATIC DISEASES, 1986, 45 (02) :136-138
[33]  
Duhaut P, 1998, ARTHRITIS RHEUM-US, V41, P701, DOI 10.1002/1529-0131(199804)41:4<701::AID-ART18>3.0.CO
[34]  
2-P
[35]   Association of NOS2 and potential effect of VEGF, IL6, CCL2 and IL1RN polymorphisms and haplotypes on susceptibility to GCA-a simultaneous study of 130 potentially functional SNPs in 14 candidate genes [J].
Enjuanes, Anna ;
Benavente, Yolanda ;
Hernandez-Rodriguez, Jose ;
Queralt, Carme ;
Yaguee, Jordi ;
Jares, Pedro ;
de Sanjose, Silvia ;
Campo, Elias ;
Cid, Maria C. .
RHEUMATOLOGY, 2012, 51 (05) :841-851
[36]  
ESHAGHIAN J, 1980, OPHTHALMOLOGY, V87, P1160
[37]  
Esteban MJ, 2001, ARTHRITIS RHEUM-US, V44, P1387, DOI 10.1002/1529-0131(200106)44:6<1387::AID-ART232>3.0.CO
[38]  
2-B
[39]   Delays in recognition and management of giant cell arteritis: results from a retrospective audit [J].
Ezeonyeji, Amara N. ;
Borg, Frances A. ;
Dasgupta, Bhaskar .
CLINICAL RHEUMATOLOGY, 2011, 30 (02) :259-262
[40]   Immuno-localisation of tumour necrosis factor and its receptors in temporal arteritis [J].
Field, M ;
Cook, A ;
Gallagher, G .
RHEUMATOLOGY INTERNATIONAL, 1997, 17 (03) :113-118